Avalo Therapeutics CMO Doyle Mittie Receives 43,500 Performance Stock Units

This Form 4 filing reports that Doyle Mittie, Chief Medical Officer of Avalo Therapeutics, Inc., received 43,500 performance stock units (PSUs) on May 21, 2026. The PSUs were originally granted on August 19, 2025, and represent a contingent right to receive shares of common stock upon achievement of certain performance goals. The Compensation Committee certified the achievement of these performance goals on May 21, 2026. The shares subject to the PSUs will fully vest on August 19, 2028, contingent on Mittie's continued service with the company through that date. Following this transaction, Mittie's total holdings increased to 47,122 shares of common stock. The transaction was reported at $0.00 per share as it represents equity compensation rather than a market purchase.